Epigenetic regulation in human melanoma: Past and future

Epigenetics

Volumn 10, Issue 2, 2015, Pages 103-121

  Sarkar, Debina ^a,b   Leung, Euphemia Y ^a,b   Baguley, Bruce C ^a   Finlay, Graeme J ^a,b   Askarian Amiri, Marjan E ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Chromatin modification; Chromatin remodeling; DNA methylation demethylation; Epigenetics; Gene regulation; Melanoma; NcRNAs

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; ARF PROTEIN; B RAF KINASE; BRG1 PROTEIN; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 1; HISTONE DEACETYLASE; HISTONE LYSINE METHYLTRANSFERASE; HOX PROTEIN; ISOCITRATE DEHYDROGENASE; KI 67 ANTIGEN; LONG UNTRANSLATED RNA; METHYL CPG BINDING PROTEIN 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA 31; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYCOMB GROUP PROTEIN; PROTEIN BCL 2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; SMALL NUCLEOLAR RNA; SPROUTY PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR MAFG; TRANSCRIPTION FACTOR RUNX2; HISTONE;

CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DNA MICROARRAY; DOWN REGULATION; EPIGENETICS; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; KERATINOCYTE; LUNG ADENOCARCINOMA; MELANOCYTE; MELANOMA; NONHUMAN; PROTEIN BINDING; PROTEIN DEPLETION; REVIEW; TISSUE DIFFERENTIATION; TRANSITIONAL CELL CARCINOMA; UPREGULATION; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MELANOMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, LONG NONCODING; SIGNAL TRANSDUCTION;

EID: 84925012591     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2014.1003746     Document Type: Review

References (167)

1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
2. Uzdensky AB, Demyanenko SV, Bibov MY. Signal transduction in human cutaneous melanoma and target drugs. Curr Cancer Drug Targets 2013; 13:843-66; PMID:23675881; http://dx.doi.org/10.2174/1568009611313080004
3. Pho LN, Leachman SA. Genetics of pigmentation and melanoma predisposition. G Ital Dermatol Venereol 2010; 145:37-45; PMID:20197744
4. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22:3092-8; PMID:12789286; http://dx.doi.org/10.1038/sj.onc.1206461
5. Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst 2014; 106: 435; PMID:24511108; http://dx.doi.org/10.1093/jnci/djt435
6. Ichii-Nakato N, Takata M, Takayanagi S, Takashima S, Lin J, Murata H, Fujimoto A, Hatta N, Saida T. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi. J Invest Dermatol 2006; 126:2111-8; PMID:16691193; http://dx.doi.org/10.1038/sj.jid.5700366
7. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012; 132:854-63; PMID:22217739; http://dx.doi.org/10.1038/jid.2011.421
8. Lee JJ, Murphy GF, Lian CG. Melanoma epigenetics: novel mechanisms, markers, and medicines. Lab Invest 2014; 94:822-38; PMID:24978641; http://dx.doi.org/10.1038/labinvest.2014.87
9. Hauptman N, Glava_c D. Long non-coding RNA in cancer. Int J Mol Sci 2013; 14:4655-69; PMID:23443164; http://dx.doi.org/10.3390/ijms14034655
10. Hombach S, Kretz M. The non-coding skin: Exploring the roles of long non-coding RNAs in epidermal homeostasis and disease. BioEssays 2013; 35:1093-100; PMID:24115003; http://dx.doi.org/10.1002/bies.201300068
11. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Genes Dev 2012; 26:1131-55; PMID:22661227; http://dx.doi.org/10.1101/gad.191999.112
12. McGill GG, Horstmann M, Widlund HR, Du J, Motyckova G, Nishimura EK, Lin YL, Ramaswamy S, Avery W, Ding HF, et al. Bcl2 regulation by the melanocyte master regulator mitf modulates lineage survival and melanoma cell viability. Cell 2002; 109:707-18; PMID:12086670; http://dx.doi.org/10.1016/S0092-8674(02)00762-6
13. Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, vanden Boorn-Konijnenberg D, Homig-Holzel C, et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014; 507:109-13; PMID:24572365; http://dx.doi.org/10.1038/nature13111
14. Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature 2014; 511:478-82; PMID:24919155; http://dx.doi.org/10.1038/nature13298
15. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011:330-9; PMID:21386836; http://dx.doi.org/10.1038/nm.2305
16. Kulis M, Esteller M. DNA methylation and cancer. Adv Genet 2010; 70:27-56; PMID:20920744; http://dx.doi.org/10.1016/B978-0-12-380866-0.60002-2
17. Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, Danielli R, Nicolay H, Coral S, Maio M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 2010; 8:56; PMID:20540720; http://dx.doi.org/10.1186/1479-5876-8-56
18. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 2006; 66:11187-93; PMID:17145863; http://dx.doi.org/10.1158/0008-5472.CAN-06-1274
19. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 2009; 19:1462-70; PMID:19491193; http://dx.doi.org/10.1101/gr.091447.109
20. Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, Nery JR, Lee L, Ye Z, Ngo QM, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009; 462:315-22; PMID:19829295; http://dx.doi.org/10.1038/nature08514
21. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012; 150:1135-46; PMID:22980977; http://dx.doi.org/10.1016/j.cell.2012.07.033
22. Gambichler T, Sand M, Skrygan M. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma Res 2013; 23:218-20; PMID:23458759; http://dx.doi.org/10.1097/CMR.0b013e32835f9bd4
23. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004; 23:4014-22; PMID:15064737; http://dx.doi.org/10.1038/sj.onc.1207505
24. Fan J, Eastham L, Varney ME, Hall A, Adkins NL, Sollars VE, Georgel P, Niles RM. Silencing and reexpression of retinoic acid receptor beta2 in human melanoma. Pigment Cell Melanoma Res 2010; 23:419-29; PMID:20374520; http://dx.doi.org/10.1111/j.1755-148X.2010.00702.x
25. Xu X-C. Tumor-suppressive activity of retinoic acid receptor-b in cancer. Cancer Lett 2007; 253:14-24; PMID:17188427; http://dx.doi.org/10.1016/j.canlet.2006.11.019
26. Tanemura A, Terando AM, Sim M-S, van Hoesel AQ, de Maat MFG, Morton DL, Hoon DSB. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009; 15:1801-7; PMID:19223509; http://dx.doi.org/10.1158/1078-0432.CCR-08-1361
27. Yi M, Yang J, Chen X, Li J, Li X, Wang L, Tan Y, Xiong W, Zhou M, McCarthy JB, et al. RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression. J Cell Physiol 2011; 226:2360-9; PMID:21660959; http://dx.doi.org/10.1002/jcp.22568
28. Straume O, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am J Pathol 2002; 161:229-37; PMID:12107107; http://dx.doi.org/10.1016/S0002-9440(10)64174-0
29. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006; 66:6080-6; PMID:16778180; http://dx.doi.org/10.1158/0008-5472.CAN-06-0157
30. van der Velden PA, Metzelaar-Blok JAW, Bergman W, Monique H, Hurks H, Frants RR, Gruis NA, Jager MJ. Promoter hypermethylation: a common cause of reduced p16INK4a expression in uveal melanoma. Cancer Res 2001; 61:5303-6; PMID:11431374
31. Hassel JC, Sucker A, Edler L, Kurzen H, Moll I, Stresemann C, Spieth K, Mauch C, Rass K, Dummer R, et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 2010; 103:820-6; PMID:20736948; http://dx.doi.org/10.1038/sj.bjc.6605796
32. Zhao W, Soejima H, Higashimoto K, Nakagawachi T, Urano T, Kudo S, Matsukura S, Matsuo S, Joh K, Mukai T. The essential ole of histoneH3 Lys9Di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island. J Biochem 2005; 137:431-40; PMID:15809347; http://dx.doi.org/10.1093/jb/mvi048
33. Hou P, Liu D, Dong J, Xing M. The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 2012; 11:286-95; PMID:22189819; http://dx.doi.org/10.4161/cc.11.2.18707
34. Fang M, Ou J, Hutchinson L, Green Michael R. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG island methylator phenotype. Mol Cell 2014; 55:904-15; PMID:25219500; http://dx.doi.org/10.1016/j.molcel.2014.08.010
35. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky Jr WE, You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544-52; PMID:19282848; http://dx.doi.org/10.1038/ng.356
36. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006; 66:6546-52; PMID:16818626; http://dx.doi.org/10.1158/0008-5472.CAN-06-0384
37. Clements EG, Mohammad HP, Leadem BR, Easwaran H, Cai Y, Van Neste L, Baylin SB. DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res 2012; 40:4334-46; PMID:22278882; http://dx.doi.org/10.1093/nar/gks031
38. Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DSB. Epigenetic biomarkers in skin cancer. Cancer Lett 2014; 342:170-7; PMID:22289720; http://dx.doi.org/10.1016/j.canlet.2012.01.020
39. van den Hurk K, Niessen HEC, Veeck J, van den Oord JJ, van Steensel MAM, zur Hausen A, van Engeland M, Winnepenninckx VJL. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim Biophys Acta 2012; 1826:89-102; PMID:22503822; 10.1016/j.bbcan.2012.03.011
40. Florenes VA, Skrede M, Jorgensen K, Nesland JM. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res 2004; 14:173-81; PMID:15179185; http://dx.doi.org/10.1097/01.cmr.0000129576.49313.26
41. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther 2004; 3:425-35; PMID:15078986; http://dx.doi.org/10.4161/cbt.3.5.985
42. Ye Y, Jin L, Wilmott JS, Hu WL, Yosufi B, Thorne RF, Liu T, Rizos H, Yan XG, Dong L, et al. PI(4,5) P2 5-phosphatase a regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nat Commun 2013; 4:1508; PMID:23443536; http://dx.doi.org/10.1038/ncomms2489
43. Martı RM, Sorolla A, Yeramian A. New therapeutic targets in melanoma. Actas Dermosifiliogr 2012; 103:579-90; PMID:22261672; http://dx.doi.org/10.1016/j.ad.2011.08.009
44. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre F, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011; 471:513-7; PMID:21430779; http://dx.doi.org/10.1038/nature09806
45. Karram S, Novy M, Saroufim M, Loya A, Taraif S, Houreih MA, Rauscher B, Habib RH, Oberkanins C, Khalifeh I. Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure. Am J Dermatopathol 2013; 35:412-8; PMID:23051629; http://dx.doi.org/10.1097/DAD.0b013e31826db181
46. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6:846-56; PMID:17060944; http://dx.doi.org/10.1038/nrc1991
47. Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CCR, Hornyak TJ. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res 2011; 9:418-29; PMID:21383005; http://dx.doi.org/10.1158/1541-7786.MCR-10-0511
48. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24:268-73; PMID:16330673; http://dx.doi.org/10.1200/JCO.2005.01.5180
49. Wu ZL, Zheng SS, Li ZM, Qiao YY, Aau MY, Yu Q. Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression. Cell Death Differ 2010; 17:801-10; PMID:19893569; http://dx.doi.org/10.1038/cdd.2009.162
50. Bishop JN, Harland M, Randerson-Moor J, Bishop DT. Management of familial melanoma. Lancet Oncol 2007; 8:46-54; PMID:17196510; http://dx.doi.org/10.1016/S1470-2045(06)71010-5
51. Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, part II: ATP-dependent chromatin remodeling. Trends Mol Med 2007; 13:373-80; PMID:17822959; http://dx.doi.org/10.1016/j.molmed.2007.07.004
52. Vinod Saladi S, Marathe H, de la Serna IL. SWItching on the transcriptional circuitry in melanoma. Epigenetics 2010; 5:469-75; PMID:20543574; http://dx.doi.org/10.4161/epi.5.6.12315
53. Saladi SV, Wong PG, Trivedi AR, Marathe HG, Keenen B, Aras S, Liew Z-Q, Setaluri V, de la Serna IL. BRG1 promotes survival of UV-irradiated melanoma cells by cooperating with MITF to activate the melanoma inhibitor of apoptosis gene. Pigment Cell Melanoma Res 2013; 26:377-91; PMID:23480510; http://dx.doi.org/10.1111/pcmr.12088
54. de la Serna IL, Ohkawa Y, Higashi C, Dutta C, Osias J, Kommajosyula N, Tachibana T, Imbalzano AN. The microphthalmia-associated transcription factor requires SWI/SNF enzymes to activate melanocytespecific genes. J Biol Chem 2006; 281:20233-41; PMID:16648630; http://dx.doi.org/10.1074/jbc.M513886200
55. Mascolo M, Vecchione M, Ilardi G, Scalvenzi M, Molea G, Di Benedetto M, Nugnes L, Siano M, De Rosa G, Staibano S. Overexpression of chromatin assembly factor-1/p60 helps to predict the prognosis of melanoma patients. BMC Cancer 2010; 10:63; PMID:20178651; http://dx.doi.org/10.1186/1471-2407-10-63
56. Bennett PE, Bemis L, Norris DA, Shellman YG. miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol Genomics 2013; 45:1049-59; PMID:24046283; http://dx.doi.org/10.1152/physiolgenomics.00116.2013
57. Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, et al. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget 2012; 3:1011-25; PMID:22948084
58. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322:1695-9; PMID:19008416; http://dx.doi.org/10.1126/science.1165395
59. Luo C, Merz PR, Chen Y, Dickes E, Pscherer A, Schadendorf D, Eichmuller SB. MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. Cancer Lett 2013; 341:240-7; PMID:23962556; http://dx.doi.org/10.1016/j.canlet.2013.08.021
60. Bonazzi VF, Stark MS, Hayward NK. MicroRNA regulation of melanoma progression. Melanoma Res 2012; 22:101-13; PMID:22209751; http://dx.doi.org/10.1097/CMR.0b013e32834f6fbb
61. Brockdorff N. Noncoding RNA and polycomb recruitment. RNA 2013; 19:429-42; PMID:23431328; http://dx.doi.org/10.1261/rna.037598.112
62. Hirota K, Miyoshi T, Kugou K, Hoffman CS, Shibata T, Ohta K. Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs. Nature 2008; 456:130-4; PMID:18820678; http://dx.doi.org/10.1038/nature07348
63. Yin Q-F, Yang L, Zhang Y, Xiang J-F, Wu Y-W, Carmichael Gordon G, Chen L-L. Long oncoding RNAs with snoRNA ends. Mol Cell 2012; 48:219-30; PMID:22959273; http://dx.doi.org/10.1016/j.molcel.2012.07.033
64. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, Chen N, Sun F, Fan Q. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res 2010; 38:5366-83; PMID:20423907; http://dx.doi.org/10.1093/nar/gkq285
65. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature 2013; 495:384-8; PMID:23446346; http://dx.doi.org/10.1038/nature11993
66. Karreth FA, Tay Y, Perna D, Ala U, Tan SM, Rust AG, DeNicola G, Webster KA, Weiss D, Perez-Mancera PA, et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAFinduced mouse model of melanoma. Cell 2011; 147:382-95; PMID:22000016; http://dx.doi.org/10.1016/j.cell.2011.09.032
67. van Heesch S, van Iterson M, Jacobi J, Boymans S, Essers P, de Bruijn E, Hao W, MacInnes A, Cuppen E, Simonis M. Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes. Genome Biol 2014; 15:R6; PMID:24393600; http://dx.doi.org/10.1186/gb-2014-15-1-r6
68. Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ, Zhou M-M. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38:662-74; PMID:20541999; http://dx.doi.org/10.1016/j.molcel.2010.03.021
69. Kretz M, Webster DE, Flockhart RJ, Lee CS, Zehnder A, Lopez-Pajares V, Qu K, Zheng GXY, Chow J, Kim GE, et al. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev 2012; 26:338-43; PMID:22302877; http://dx.doi.org/10.1101/gad.182121.111
70. Zhu L, Xu P-C. Downregulated LncRNA-ANCR promotes osteoblast differentiation by targeting EZH2 and regulating Runx2 expression. Biochem Biophys Res Commun 2013; 432:612-7; PMID:23438432; http://dx.doi.org/10.1016/j.bbrc.2013.02.036
71. Van Kilsdonk JW, Bergers M, Van Kempen LC, Schalkwijk J, Swart GW. Keratinocytes drive melanoma invasion in a reconstructed skin model. Melanoma Res 2010; 20:372-80; PMID:20700063; http://dx.doi.org/10.1097/CMR.0b013e32833d8d70
72. Kretz M, Siprashvili Z, Chu C, Webster DE, Zehnder A, Qu K, Lee CS, Flockhart RJ, Groff AF, Chow J, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature 2013; 493:231-5; PMID:23201690; http://dx.doi.org/10.1038/nature11661
73. Kretz M. TINCR, staufen1, and cellular differentiation. RNA Biol 2013; 10:1597-601; PMID:24019000; http://dx.doi.org/10.4161/rna.26249
74. Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, Khavari PA. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res 2012; 22:1006-14; PMID:22581800; http://dx.doi.org/10.1101/gr.140061.112
75. Li R, Zhang L, Jia L, Duan Y, Li Y, Bao L, Sha N. Long non-coding RNA BANCR promotes proliferation in malignant melanoma by regulating MAPK pathway activation. PLoS ONE 2014; 9:e100893; PMID:24967732; http://dx.doi.org/10.1371/journal.pone.0100893
76. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, Goodnough LH, Helms JA, Farnham PJ, Segal E, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129:1311-23; PMID:17604720; http://dx.doi.org/10.1016/j.cell.2007.05.022
77. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai M-C, Hung T, Argani P, Rinn JL, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464:1071-6; PMID:20393566; http://dx.doi.org/10.1038/nature08975
78. Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013; 32:1616-25; PMID:22614017; http://dx.doi.org/10.1038/onc.2012.193
79. Yang Z, Zhou L, Wu L-M, Lai M-C, Xie H-Y, Zhang F, Zheng S-S. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol, 2011:1243-50; PMID:21327457; http://dx.doi.org/10.1245/s10434-011-1581-y
80. Tang L, Zhang W, Su B, Yu B. Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int 2013; 2013:7; PMID:23862139; 10.1155/2013/251098
81. Tian Y, Zhang X, Hao Y, Fang Z, He Y. Potential roles of abnormally expressed long noncoding RNA UCA1 and malat-1 in metastasis of melanoma. Melanoma Res 2014; 24:335-41; PMID:24892958; http://dx.doi.org/10.1097/CMR.0000000000000080
82. Wu L, Murat P, Matak-Vinkovic D, Murrell A, Balasubramanian S. Binding interactions between long noncoding RNA HOTAIR and PRC2 proteins. Biochemistry 2013; 52:9519-27; PMID:24320048; http://dx.doi.org/10.1021/bi401085h
83. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, Jiang L, Zhang Y, Dou J. MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. STEM CELLS 2014; 32:2858-68; PMID:25070049; http://dx.doi.org/10.1002/stem.1795
84. Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, Perera RJ. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 2011; 71:3852-62; PMID:21558391; http://dx.doi.org/10.1158/0008-5472.CAN-10-4460
85. Mazar J, Zhao W, Khalil AM, Lee B, Shelley J, Govindarajan SS, Yamamoto F, Ratnam M, Aftab MN, Collins S, et al. The functional characterization of long noncoding RNA SPRY4-IT1 in human melanoma cells. Oncotarget 2014; 5:8959-69; PMID:25344859
86. Sun M, Liu XH, Lu KH, Nie FQ, Xia R, Kong R, Yang JS, Xu TP, Liu YW, Zou YF, et al. EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition. Cell Death Dis 2014; 5:e1298; PMID:24967960; http://dx.doi.org/10.1038/cddis.2014.256
87. Wu C-F, Tan G-H, Ma C-C, Li L. The non-coding RNA Llme23 drives the malignant property of human melanoma cells. J Genet Genomics 2013; 40:179-88; PMID:23618401; http://dx.doi.org/10.1016/j.jgg.2013.03.001
88. Pasmant E, Laurendeau I, H_eron D, Vidaud M, Vidaud D, Bi_eche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67:3963-9; PMID:17440112; http://dx.doi.org/10.1158/0008-5472.CAN-06-2004
89. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z, Sharpless NE. Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA Correlates with atherosclerosis risk. PLoS Genet 2010; 6:e1001233; PMID:21151960; http://dx.doi.org/10.1371/journal.pgen.1001233
90. Maccioni L, Rachakonda P, Bermejo J, Planelles D, Requena C, Hemminki K, Nagore E, Kumar R. Variants at the 9p21 locus and melanoma risk. BMC Cancer 2013; 13:325; PMID:23816148; http://dx.doi.org/10.1186/1471-2407-13-325
91. Sato K, Nakagawa H, Tajima A, Yoshida K, Inoue I. ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. Oncol Rep 2010; 24:701-7; PMID:20664976
92. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 2011; 30:1956-62; PMID:21151178; http://dx.doi.org/10.1038/onc.2010.568
93. Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, Xu TP, Xia R, Yang JS, De W, et al. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. Oncotarget 2014; 5:2276-92; PMID:24810364
94. Congrains A, Kamide K, Oguro R, Yasuda O, Miyata K, Yamamoto E, Kawai T, Kusunoki H, Yamamoto H, Takeya Y, et al. Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis 2012; 220:449-55; PMID:22178423; http://dx.doi.org/10.1016/j.atherosclerosis.2011.11.017
95. Wan G, Mathur R, Hu X, Liu Y, Zhang X, Peng G, Lu X. Long non-coding RNA ANRIL (CDKN2BAS) is induced by the ATM-E2F1 signaling pathway. Cell Signal 2013; 25:1086-95; PMID:23416462; http://dx.doi.org/10.1016/j.cellsig.2013.02.006
96. Jukic D, Rao U, Kelly L, Skaf J, Drogowski L, Kirkwood J, Panelli M. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010; 8:27; PMID:20302635; http://dx.doi.org/10.1186/1479-5876-8-27
97. Bochenek G, Hasler R, El Mokhtari N-E, K€onig IR, Loos BG, Jepsen S, Rosenstiel P, Schreiber S, Schaefer AS. The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. Hum Mol Genet 2013; 22:4516-27; PMID:23813974; http://dx.doi.org/10.1093/hmg/ddt299
98. Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, Ren B, Fu X-D, Topol EJ, Rosenfeld MG, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-Y signalling response. Nature 2011; 470:264-8; PMID:21307941; http://dx.doi.org/10.1038/nature09753
99. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 2006; 7:667-77; PMID:16921403; http://dx.doi.org/10.1038/nrm1987
100. Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, Li X. Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 2012; 41:276-84; PMID:22576688; http://dx.doi.org/10.3892/ijo.2012.1443
101. Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, Mo YY. Long non-coding RNA UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death Dis 2014; 5:e1008; PMID:24457952; http://dx.doi.org/10.1038/cddis.2013.541
102. Gutschner T, Hammerle M, Diederichs S. MALAT1 – a paradigm for long noncoding RNA function in cancer. J Mol Med (Berl) 2013; 91:791-801; PMID:23529762; http://dx.doi.org/10.1007/s00109-013-1028-y
103. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, et al. PRC2 loss amplifies rasdriven transcription and confers sensitivity to BRD4-based therapies. Nature 2014; 514:247-51; PMID:25119042; 10.1038/nature13561
104. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 2004; 23:5215-26; PMID:15133491; http://dx.doi.org/10.1038/sj.onc.1207647
105. Liu W, Luo Y, Dunn JH, Norris DA, Dinarello CA, Fujita M. Dual role of apoptosis-associated speck-like protein containing a CARD (ASC) in tumorigenesis of human melanoma. J Invest Dermatol 2013; 133:518-27; PMID:22931929; http://dx.doi.org/10.1038/jid.2012.317
106. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 2006; 66:11187-93; PMID:17145863; http://dx.doi.org/10.1158/0008-5472.CAN-06-1274
107. Venza M, Visalli M, Biondo C, Oteri R, Agliano F, Morabito S, Teti D, Venza I. Epigenetic marks responsible for cadmium-induced melanoma cell overgrowth. Toxicology in Vitro 2015; 29:242-50; PMID:25448810; http://dx.doi.org/10.1016/j.tiv.2014.10.020
108. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 2004; 95:962-8; PMID:15596045; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03184.x
109. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 2008; 21:545-58; PMID:18627528; http://dx.doi.org/10.1111/j.1755-148X.2008.00484.x
110. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A. Aberrant DNA methylation in malignant melanoma. Melanoma Res 2010; 20:253-65; PMID:20418788; http://dx.doi.org/10.1097/CMR.0b013e328338a35a
111. Worm J, Bartkova J, Kirkin AF, Straten P, Zeuthen J, Bartek J, Guldberg P. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 2000; 19:5111-5; PMID:11042700; http://dx.doi.org/10.1038/sj.onc.1203891
112. Curry JL, Richards HW, Huttenbach YT, Medrano EE, Reed JA. Different expression patterns of p27KIP1 and p57KIP2 proteins in benign and malignant melanocytic neoplasms and in cultured human melanocytes. J Cutan Pathol 2009; 36:197-205; PMID:18647205; http://dx.doi.org/10.1111/j.1600-0560.2008.00998.x
113. Mori T, O’Day SJ, Umetani N, Martinez SR, Kitago M, Koyanagi K, Kuo C, Takeshima T-L, Milford R, Wang H-J, et al. Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 2005; 23:9351-8; PMID:16361635; http://dx.doi.org/10.1200/JCO.2005.02.9876
114. McGuinness C, Wesley UV. Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation. Front Biosci 2008; 13:2435-43; PMID:17981724; http://dx.doi.org/10.2741/2856
115. Matic IZ, Ethordic M, Grozdanic N, Damjanovic A, Kolundzija B, Eric-Nikolic A, Dzodic R, Sasic M, Nikolic S, Dobrosavljevic D, et al. Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. BMC Immunol 2012; 13:48; PMID:22908963; http://dx.doi.org/10.1186/1471-2172-13-48
116. Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, Chu H, Kuan PF, Hao H, Carson C, Berwick M, et al. DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res 2011; 24:352-60; PMID:21375697; http://dx.doi.org/10.1111/j.1755-148X.2011.00828.x
117. Ekstrom EJ, Sherwood V, Andersson T. Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion. PLoS ONE 2011; 6:e18674; PMID:21494614; http://dx.doi.org/10.1371/journal.pone.0018674
118. Sharma BK, Smith CC, Laing JM, Rucker DA, Burnett JW, Aurelian L. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions. Dermatology 2006; 213:192-9; PMID:17033167; http://dx.doi.org/10.1159/000095035
119. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene 2006; 25:2873-84; PMID:16407841; http://dx.doi.org/10.1038/sj.onc.1209319
120. Muthusamy V, Premi S, Soper C, Platt J, Bosenberg M. The hematopoietic stem cell regulatory gene latexin has tumor-suppressive properties in malignant melanoma. J Invest Dermatol 2013; 133:1827-33; PMID:23364479; http://dx.doi.org/10.1038/jid.2013.48
121. Chen XJ, Zhang K, Xin Y, Jiang G. Oncolytic adenovirus-expressed RNA interference of O-methylguanine DNA methyltransferase activity may enhance the antitumor effects of temozolomide. Oncol Lett 2014; 8:2201-2; PMID:25295108
122. Takeuchi T, Adachi Y, Sonobe H, Furihata M, Ohtsuki Y. A ubiquitin ligase, skeletrophin, is a negative regulator of melanoma invasion. Oncogene 2006; 25:7059-69; PMID:16715130; http://dx.doi.org/10.1038/sj.onc.1209688
123. Shi X, Deepak V, Wang L, Ba X, Komori T, Zeng X, Liu W. Thrombospondin-1 is a putative target gene of Runx2 and Runx3. Int J Mol Sci 2013; 14:14321-32; PMID:23846726; http://dx.doi.org/10.3390/ijms140714321
124. Parrillas V, Martinez-Munoz L, Holgado BL, Kumar A, Cascio G, Lucas P, Rodriguez-Frade JM, Malumbres M, Carrera AC, van Wely KH, et al. Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells. Cell Mol Life Sci 2013; 70:545-58; PMID:23001011; http://dx.doi.org/10.1007/s00018-012-1145-8
125. Tokita T, Maesawa C, Kimura T, Kotani K, Takahashi K, Akasaka T, Masuda T. Methylation status of the SOCS3 gene in human malignant melanomas. Int J Oncol 2007; 30:689-94; PMID:17273770
126. Fang S, Liu B, Sun Q, Zhao J, Qi H, Li Q. Platelet factor 4 inhibits IL-17/Stat3 pathway via upregulation of SOCS3 expression in melanoma. Inflammation 2014; 37:1744-50; PMID:24799320; http://dx.doi.org/10.1007/s10753-014-9903-4
127. Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS ONE 2011; 6:e26121; PMID:22028813; http://dx.doi.org/10.1371/journal.pone.0026121
128. Das AM, Seynhaeve AL, Rens JA, Vermeulen CE, Koning GA, Eggermont AM, Ten Hagen TL. Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration. Angiogenesis 2014; 17:163-77; PMID:24221409; http://dx.doi.org/10.1007/s10456-013-9385-2
129. Furuta J, Kaneda A, Umebayashi Y, Otsuka F, Sugimura T, Ushijima T. Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res 2005; 15:15-20; PMID:15714116; http://dx.doi.org/10.1097/00008390-200502000-00004
130. Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD, Castillo-Martin M, Fox K, Cordon-Cardo C, et al. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma. J Am Acad Dermatol 2014; 70:1036-44; PMID:24698703; http://dx.doi.org/10.1016/j.jaad.2014.01.914
131. Sigalotti L, Coral S, Nardi G, Spessotto A, Cortini E, Cattarossi I, Colizzi F, Altomonte M, Maio M. Promotermethylation controls the expression ofMAGE2, 3 and 4 genes in human cutaneous melanoma. J Immunother 2002; 25:16-26; PMID:11924907; http://dx.doi.org/10.1097/00002371-200201000-00002
132. Dillman RO, Depriest C, McClure SE. High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. Cancer Biother Radiopharm 2014; 29:53-7; PMID:24380630; http://dx.doi.org/10.1089/cbr.2013.1565
133. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006; 25:6975-85; PMID:16715135; http://dx.doi.org/10.1038/sj.onc.1209678
134. Wada K, Maesawa C, Akasaka T, Masuda T. Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dermatol 2004; 122:805-11; PMID:15086568; http://dx.doi.org/10.1111/j.0022-202X.2004.22308.x
135. Wei T, Orfanidis K, Xu N, Janson P, Stahle M, Pivarcsi A, Sonkoly E. The expression of microRNA-203 during human skin morphogenesis. Exp Dermatol 2010; 19:854-6; PMID:20698882; http://dx.doi.org/10.1111/j.1600-0625.2010.01118.x
136. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci 2008; 105:13421-6; PMID:18755897; http://dx.doi.org/10.1073/pnas.0801613105
137. Zhang L, Stokes N, Polak L, Fuchs E. Specific icroRNAs are preferentially expressed by skin stem cells to balance self-renewal and early lineage commitment. Cell Stem Cell 2011; 8:294-308; PMID:21362569; http://dx.doi.org/10.1016/j.stem.2011.01.014
138. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10:593-601; PMID:18376396; http://dx.doi.org/10.1038/ncb1722
139. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283:14910-4; PMID:18411277; http://dx.doi.org/10.1074/jbc.C800074200
140. Wang D, Zhang Z, O’Loughlin E, Wang L, Fan X, Lai EC, Yi R. MicroRNA-205 controls neonatal expansion of skin stem cells by modulating the PI(3)K pathway. Nat Cell Biol 2013; 15:1153-63; PMID:23974039; http://dx.doi.org/10.1038/ncb2827
141. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh S-S, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009; 16:498-509; PMID:19962668; http://dx.doi.org/10.1016/j.ccr.2009.10.014
142. Igoucheva O, Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 2009; 379:790-4; PMID:19126397; http://dx.doi.org/10.1016/j.bbrc.2008.12.152
143. Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010; 126:2553-62; PMID:19830692; http://dx.doi.org/10.1002/ijc.24960
144. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, Zhang LJ, Thorne RF, Wilmott J, Scolyer RA, et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci 2011; 108:15840-5; PMID:21896753; http://dx.doi.org/10.1073/pnas.1019312108
145. Streicher KL, Zhu W, Lehmann KP, Georgantas RW, Morehouse CA, Brohawn P, Carrasco RA, Xiao Z, Tice DA, Higgs BW, et al. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012; 31:1558-70; PMID:21860416; http://dx.doi.org/10.1038/onc.2011.345
146. Bemis LT, Chen R, Amato CM, Classen EH, Robinson SE, Coffey DG, Erickson PF, Shellman YG, Robinson WA. MicroRNA-137 targets microphthalmiaassociated transcription factor in melanoma cell lines. Cancer Res 2008; 68:1362-8; PMID:18316599; http://dx.doi.org/10.1158/0008-5472.CAN-07-2912
147. Chen J, Feilotter HE, Par_e GC, Zhang X, Pemberton JGW, Garady C, Lai D, Yang X, Tron VA. Micro-RNA-193b Represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010; 176:2520-9; PMID:20304954; http://dx.doi.org/10.2353/ajpath.2010.091061
148. Haflidad_ottir BS, Bergsteinsd_ottir K, Praetorius C, Steingr_ımsson E. miR-148 regulates mitf in melanoma cells. PLoS ONE 2010; 5:e11574; PMID:20644734; http://dx.doi.org/10.1371/journal.pone.0011574
149. Dar AA, Majid S, Rittsteuer C, de Semir D, Bezrookove V, Tong S, Nosrati M, Sagebiel R, Miller JR, Kashani-Sabet M. The role of miR-18b inMDM2-p53 pathway signaling and melanoma progression. J Natl Cancer Inst 2013; 105:433-42; PMID:23365201; http://dx.doi.org/10.1093/jnci/djt003
150. Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, Marquez VE, Zhang Q, Norris DA, Shellman YG. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol 2013; 133:1286-93; PMID:23190898; http://dx.doi.org/10.1038/jid.2012.400
151. Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 2011; 286:16606-14; PMID:21454583; http://dx.doi.org/10.1074/jbc.M111.227611
152. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, et al. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS ONE 2011; 6:e18936; PMID:21541354; http://dx.doi.org/10.1371/journal.pone.0018936
153. Noguchi S, Mori T, Otsuka Y, Yamada N, Yasui Y, Iwasaki J, Kumazaki M, Maruo K, Akao Y. Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. J Biol Chem 2012; 287:11769-77; PMID:22354972; http://dx.doi.org/10.1074/jbc.M111.325027
154. Yamazaki H, Chijiwa T, Inoue Y, Abe Y, Suemizu H, Kawai K, Wakui M, Furukawa D, Mukai M, Kuwao S, et al. Overexpression of the miR-34 family suppresses invasive growth of malignant melanoma with the wild-type p53 gene. Exp Ther Med 2012; 3:793-6; PMID:22969970
155. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pitta C, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011; 30:1990-2007; PMID:21468029; http://dx.doi.org/10.1038/emboj.2011.102
156. Gaziel-Sovran A, Segura Miguel F, Di Micco R, Collins Mary K, Hanniford D, Vega-Saenzde Miera E, Rakus John F, Dankert John F, Shang S, Kerbel Robert S, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011; 20:104-18; PMID:21741600; http://dx.doi.org/10.1016/j.ccr.2011.05.027
157. Segura MF, Hanniford D, Menendez S, Reavie L, Zou X, Alvarez-Diaz S, Zakrzewski J, Blochin E, Rose A, Bogunovic D, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci 2009; 106:1814-9; PMID:19188590; http://dx.doi.org/10.1073/pnas.0808263106
158. Muller DW, Bosserhoff AK. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008; 27:6698-706; PMID:18679415; http://dx.doi.org/10.1038/onc.2008.282
159. Felli N, Felicetti F, Lustri AM, Errico MC, Bottero L, Cannistraci A, De Feo A, Petrini M, Pedini F, Biffoni M, et al. miR-126&126* restored expressions play a tumor suppressor role by directly regulating ADAM9 and MMP7 in melanoma. PLoS ONE 2013; 8: e56824; PMID:23437250; http://dx.doi.org/10.1371/journal.pone.0056824
160. Dynoodt P, Speeckaert R, De Wever O, Chevolet I, Brochez L, Lambert J, Van Gele M. miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells. Int J Cancer 2013; 42:1443-51; PMID:23404256; http://dx.doi.org/10.3892/ijo.2013.1823
161. Luo C, Tetteh PW, Merz PR, Dickes E, Abukiwan A, Hotz-Wagenblatt A, Holland-Cunz S, Sinnberg T, Schittek B, Schadendorf D, et al. miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. J Invest Dermatol 2013; 133:768-75; PMID:23151846; http://dx.doi.org/10.1038/jid.2012.357
162. Boyle GM, Woods SL, Bonazzi VF, Stark MS, Hacker E, Aoude LG, Dutton-Regester K, Cook AL, Sturm RA, Hayward NK. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 2011; 24:525-37; PMID:21435193; http://dx.doi.org/10.1111/j.1755-148X.2011.00849.x
163. Liu S, Kumar SM, Lu H, Liu A, Yang R, Pushparajan A, Guo W, Xu X. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kB1–Snail1 pathway in melanoma. J Pathol 2012; 226:61-72; PMID:22131135; http://dx.doi.org/10.1002/path.2964
164. Liu S, Tetzlaff MT, Cui R, Xu X. miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol 2012; 181:1823-35; PMID:22982443; http://dx.doi.org/10.1016/j.ajpath.2012.07.009
165. Wagenseller AG, Shada A, D’Auria KM, Murphy C, Sun D, Molhoek KR, Papin JA, Dutta A, Slingluff CL, Jr. MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. J Transl Med 2013; 11:218; PMID:24047116; http://dx.doi.org/10.1186/1479-5876-11-218
166. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010; 8:27; PMID:20302635; http://dx.doi.org/10.1186/1479-5876-8-27
167. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS. Downregulation of micro-RNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011; 6:388-94; PMID:21081840; http://dx.doi.org/10.4161/epi.6.3.14056